October 11, 2016 / 12:21 PM / 9 months ago

BRIEF-Allergan says FDA accepts supplemental new drug application for avycaz

1 Min Read

Oct 11 (Reuters) - Allergan Plc:

* FDA accepts supplemental new drug application (SNDA) for avycaz (ceftazidime and avibactam)

* Allergan plc - FDA is expected to take action on filing in q1 of 2017.

* Allergan - application seeks to expand avycaz label to include phase 3 clinical data for treatment of complicated urinary tract infections

* Allergan plc - application included results from a phase 3 study evaluating efficacy and safety of avycaz for treatment of patients with cuti Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below